With AbbVie's emraclidine failure removing a significant competitive threat for BMY's Cobenfy, I think this stock has strong potential to grow, especi...
Read
More
With AbbVie's emraclidine failure removing a significant competitive threat for BMY's Cobenfy, I think this stock has strong potential to grow, especially with analysts suggesting it could evolve into a $5 billion family of products. I'm bullish on BMY for the coming weeks.
I've been watching Bristol Myers closely and it's finally starting to show some life after being a laggard for years. The recent price action suggests...
Read
More
I've been watching Bristol Myers closely and it's finally starting to show some life after being a laggard for years. The recent price action suggests it could be a strong long play, particularly on any pullbacks. This stock seems poised for a breakout, and I'm ready to get in.